BillionToOneBLLN +2.04%13 EPS without NRI is $0.48 as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, BillionToOne ranks worse than 624999.38% on this metric.
BillionToOne's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $0.34.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.48.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BillionToOne's EPS without NRI or its related term are showing as below:
BLLN's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.75 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BillionToOne's EPS (Diluted) for the
three
months ended in Mar. 2026 was $0.34.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.48.
BillionToOne's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.39.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.56.
BillionToOne (NAS:BLLN) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BillionToOne EPS without NRI Related Terms
BillionToOne EPS without NRI Historical Data
* Premium members only.
The historical data trend for BillionToOne's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLN vs SHC, VCYT, RDNT: EPS without NRI Comparison
For the Diagnostics & Research subindustry, BillionToOne's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BillionToOne's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a EPS without NRI of $0.48 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #999999 out of 160 companies in the Medical Diagnostics & Research industry.
Is BillionToOne's EPS without NRI too high?
BillionToOne's current EPS without NRI is $0.48. The Medical Diagnostics & Research industry median EPS without NRI is 10.75. BillionToOne's value of $0.48 is 95.5% below this industry median. Based on the distribution chart, BillionToOne ranks #999999 out of 160 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's EPS without NRI compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #999999 out of 160 companies for EPS without NRI. This places BillionToOne in the lower half of its industry. The industry median EPS without NRI is 10.75. BillionToOne's value of $0.48 is 95.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.75, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current EPS without NRI of $0.48 is 95.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current EPS without NRI is $0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current EPS without NRI of $0.48. The current EPS without NRI is $0.48 and 95.5% below the Medical Diagnostics & Research industry median of 10.75. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BillionToOne (BLLN), the current EPS without NRI is $0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 